Moreover, the range of biomarkers to be used for the diagnosis of AD was further limited to Aβ and tau in the IWG criteria since 2014, and the 2018 and 2024 criteria by the NIA‐AA and the AA.1, 26, 28, 29. The gene discussed is MAPT; the disease is Alzheimer disease.